For the Inventor, By the Inventor

Enter assignee name

Marlborough, MA, United States of America

Phio Pharmaceuticals Corp.

USPTO Granted Patents = 24

% Expired Patents = 20.8

EPO Patents = 10

Trademarks = 1

Forward Citations = 197

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

William Salomon (14 out of 28 patents)

Joanne Kamens (14 out of 30 patents)

Tod M Woolf (14 out of 50 patents)

4. Anastasia Khvorova (14 out of 207 patents)

5. James Cardia (13 out of 23 patents)

6. Dmitry Samarsky (10 out of 22 patents)

7. Pamela A Pavco (7 out of 13 patents)

8. Karen G Bulock (5 out of 8 patents)

9. Lyn Libertine (5 out of 8 patents)

10. Michael Francis Byrne (3 out of 14 patents)

11. Gerard Cauwenbergh (2 out of 2 patents)

12. Michelle Miller (1 out of 2 patents)

13. Joke Hedwig Vandesompele (1 out of 1 patent)

14. Gert Van Peer (1 out of 1 patent)

15. Alexey Wolfson (1 out of 2 patents)

24 patents: Sort by Forward Citations

1. 12753407 - CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY (2026-10-06),

2. 12544344 - TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS (2026-02-10),

3. 11926828 - Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 (2024-03-12),

4. 11667915 - RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality (2023-06-06),

5. 11584933 - RNA interference in ocular indications (2023-02-21),

6. 11396654 - Neutral nanotransporters (2022-07-26),

7. 11279934 - Methods for treating cancer using nucleic acids targeting MDM2 or MYCN (2022-03-22),

8. 11254940 - Inhibition of MAP4K4 through RNAi (2022-02-22),

9. 11118178 - Reduced size self-delivering RNAI compounds (2021-09-14),

10. 11021707 - Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA (2021-06-01),

11. 11001845 - Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) (2021-05-11),

12. 10934550 - Immunotherapy of cancer (2021-03-02),

13. 10913948 - RNA interference in dermal and fibrotic indications (2021-02-09),

14. 10900039 - Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 (2021-01-26),

15. 10876119 - Reduced size self-delivering RNAI compounds (2020-12-29),

Company Overview

Phio Pharmaceuticals Corp. is a biotechnology company based in Marlborough, Massachusetts, focused on developing innovative therapies for cancer and other diseases. The company specializes in its proprietary INTASYL platform, which enables the delivery of RNA-based therapeutics directly into cells, enhancing the efficacy of treatments. Phio is dedicated to advancing its research in immuno-oncology and other therapeutic areas, aiming to improve patient outcomes through cutting-edge science and technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#19 in Marlborough, MA

#834 in Massachusetts

#13,895 in US

#26,686 in the World

Marlborough, MA, United States of America

Phio Pharmaceuticals Corp.

Forward Citations = 197

25 inventors:

William Salomon (14 out of 28 patents)

Joanne Kamens (14 out of 30 patents)

Tod M Woolf (14 out of 50 patents)

4. Anastasia Khvorova (14 out of 207 patents)

5. James Cardia (13 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Phio Pharmaceuticals Corp.. Retrieved from https://idiyas.com/company/phio-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…